Piper Sandler analyst Edward Tenthoff raised the firm’s price target on Point Biopharma to $16 from $14 and keeps an Overweight rating on the shares after the company hosted an investor day and highlighted its commercial readiness in anticipation of positive Phase III SPLASH data on Lantheus-partnered PNT-2004 in the second half of the year.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on PNT:
- Point Biopharma to host virtual investor day
- Point Biopharma appoints Bridget Martell to board of directors
- POINT Biopharma to Host Virtual Investor Day on Tuesday, June 20, 2023
- POINT Biopharma Announces FRONTIER Trial-in-Progress Poster Presentation at ASCO
- POINT Biopharma Makes Strategic Investment in Commercial-Scale Alpha-Emitting Isotope Manufacturer
